



PCT/BE03/00172



INVESTOR IN PEOPLE

REC'D 11 NOV 2003	
WIPO	PCT


The Patent Office  
Concept House  
Cardiff Road  
Newport  
South Wales  
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed *AmB. Jones*


Dated 8 October 2003

**PRIORITY DOCUMENT**  
SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH  
RULE 17.1(a) OR (b)

Patents Form 1/77

Patents Act 1977  
(Rule 16)The  
Patent  
Office04NOV02 E760548-1 D10059  
P01/7700 0.00-0225566.9**Request for grant of a patent**

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)



The Patent Office

Cardiff Road  
Newport  
South Wales  
NP9 1RH**1. Your reference**

LRD-GB-3-413

**2. Patent application number**

(The Patent Office will fill in this part)

0225566.9

**3. Full name, address and postcode of the or of each applicant (underline all surnames)**

K.U.Leuven Research and Development - Groot Begijnhof 59 - 3000 Leuven

Represented by Dr. Ivo Roelants, IPR Officer

Patents ADP number (if you know it)

If the applicant is a corporate body, give the country/state of its incorporation

Belgium

8070948001

**4. Title of the invention**

Autism gene

**5. Name of your agent (if you have one)**

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

K.U.Leuven R&amp;D

care off:

Hubert Velge

Neaves Cottage

Neaves Lane - Glyndebourne

East Sussex BN8 5UA

Patents ADP number (if you know it)

8007916003

**6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number**

Country

Priority application number  
(if you know it)Date of filing  
(day / month / year)**7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application**

Number of earlier application

Date of filing  
(day / month / year)**8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if**a) any applicant named in part 3 is not an inventor, or  
b) there is an inventor who is not named as an applicant, or

c) any named applicant is a corporate body.

See note (d))

Yes

Patents Form 1/77

**Patents Form 1/77**

9. Enter the number of sheets for any of the following items you are filing with this form.  
Do not count copies of the same document

Continuation sheets of this form

Description

34

Claim(s)

Abstract

TDM

Drawing(s)

5 only

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

2

Request for preliminary examination and search (Patents Form 9/77)

Request for substantive examination (Patents Form 10/77)

Any other documents (please specify)

1 fax cover sheet

1 fee sheet with request for fax back service

11.

I/We request the grant of a patent on the basis of this application.

Dr. Ivo Roelants - IPR Officer

Signature

Date

04/11/2002

12. Name and daytime telephone number of person to contact in the United Kingdom

Hubert Volge  
+44 7940 540 397**Warning**

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

**Notes**

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

**Patents Form 1/77**

## AUTISM GENE

### Field of the Invention

5

The invention relates to the area of autism. More particularly, the invention relates to detection of the loss and/or alteration of wild-type neurobeachin (NBEA) genes in cells or tissues and preferably in neural tissues. More particularly the present invention concerns genes containing mutations associated with autism its onset and development and also to the encoded proteins of said genes associated with autism, its onset and development and the use of said genes, encoded proteins or protein isoforms. The invention thus also relates to methods of screening for, diagnosis and treatment of autism in human subjects e.g., clinical screening, diagnosis, prognosis, therapy and prophylaxis, as well as for drug screening and drug development.

### 15 Background of the Invention

Autism is a severe developmental disorder of the central nervous system characterized by the clinical triad of abnormal language development, disturbance of social skills and particular behavioral features. The disorder starts at young age, has a variable severity and additional medical problems often appear such as mental retardation (75%) or epilepsy (15%). The prevalence of autism is estimated at about 1/1000 to 1/2000. Because of its high prevalence and the need for a lifelong medical and pedagogic supervision, autism is a major burden not only for the families involved but also for public health in general. In 5-10% of the cases, autism is a symptom of a recognizable disorder but in most cases, the cause of autism is not known, and then called "idiopathic autism".

The pathogenesis of autism is not known. A variety of structural brain anomalies have been reported in MRI or postmortem studies, but so far, the most consistent neuropathological findings in autism are abnormalities in the cerebellum, more specifically a decreased number of Purkinje cells were found in 21 of all 23 reported postmortem cases. It is now clear that the cerebellum has an important role in diverse higher cognitive functions, such as the language and emotional control, besides its role in motor control. For these reasons, autism research has recently focused more on the cerebellum. Postmortem studies have implicated the glutamate

neurotransmitter system in autism, and reduced levels of the anti-apoptotic protein bcl2 were demonstrated. Nevertheless, a single coherent theory explaining the pathogenesis of autism is lacking.

5 Family and twin studies have revealed that autism has a genetic origin, inherited as a polygenic disorder, with an estimated 2 to 10 interacting loci. The identification of the genes involved in the origin of autism is an appealing way to gain further insight. At present no genes for idiopathic autism are known. Results of association studies with candidate genes did not yield  
10 consistent results. Eight large genome screens failed to define small chromosomal regions harboring susceptibility loci for autism, but several suggestive regions have emerged. Hence, there is a need for new ways to screen for autism. Positional cloning through chromosomal aberrations associated with autism is an alternative means to identify genes involved in autism.

Diagnosis of autism presents difficulties in its own right, and a number of modalities have been  
15 proposed primarily based upon psychiatric evaluations. A number of different therapies have been attempted in an effort to cure autism or at least lessen the clinical symptoms thereof. Such have included drug therapies as well as psychiatric care and attempted counseling. In general, results of such treatments have been disappointing, and autism remains very difficult to effectively treat, particularly in severe cases.

20

In a study of 525 patients with idiopathic autism, we now identified four patients with idiopathic autism carrying a *de novo* balanced chromosomal aberration, three reciprocal translocations, one paracentric inversion. Positional cloning of the breakpoints was initiated; in one patient, (patient CME3) carrying a t(5;13)(q13.3;q14.3), the translocation disrupted the  
25 gene coding for neurobeachin (NBEA), located on chromosome 13. Disruption of the gene was shown by means of FISH as well as of Southern blot. The breakpoint on chromosome 5q13.3 did not disrupt any gene.

The *de novo* occurrence of autism and disruption of the neurobeachin gene are demonstrates  
30 that neurobeachin haploinsufficiency is involved autism.

### Summary of the Invention

- A first aspect of the invention is a method and or a kit of screening for autism in a subject, to establish a diagnosis of autism or give a prognosis. The methods comprise detecting a loss of function, all or part of, of the human neurobeachin (NBEA) in a tissue and preferably of a nervous tissue of a subject. The loss of function, all or part of, is indicative of the likelihood of occurrence of autism in the subject. Any suitable sample, cell sample or tissue sample of a subject may be used, with nervous samples being more preferred or samples of the central nervous system being most preferred, e.g., cerebellar samples, cerebral samples, and the like.
- The detection step may be carried out by determining protein level directly, or by detecting NBEA DNA or RNA changes in expression in a sample obtained from the subject. In addition the detection step can be carried out by assessing the function of NBEA, by measuring either the enzyme activity of the protein or its binding capacities to any substrate, of any kind (organic or inorganic or bio- molecules).
- As a further aspect, the present invention provides a method of screening for autism in a subject, comprising detecting the presence or absence of a mutation or a polymorphism in the *Nbea* gene, where the presence of such mutation or polymorphism indicates that the subject is afflicted with, or is at increased risk of developing, autism. Subjects may be heterozygous or homozygous for the mutation. The presence or absence of a mutation or polymorphism may be detected in any suitable cell or tissue sample from the subject, e.g., peripheral white blood cells, skin samples, tissue biopsies, and the like.
- The polymorphism may be a missense mutation, nonsense mutation, insertion mutation, or deletion mutation and may occur in exon or intron sequences, or in upstream or down-stream regulatory regions of the *Nbea* gene. Preferably, the mutation results in a functional change of the NBEA protein or in change in expression of the corresponding gene. The mutation screened for is preferably in the mRNA sequence of *Nbea*.
- The foregoing method may also be carried out by detecting an ineffective form of NBEA.
- Another aspect of the present invention is the isolation of a full length human NBEA cDNA, which will be useful in the production of recombinant NBEA, which can be used for the elucidation of the function of NBEA (e.g. screening for binding partners). Another aspect of

the present invention is the use of full length human NBEA cDNA for producing a cellular model to unravel the function of NBEA (in yeast or in mammalian cell-lines such as AtT-20 or Neuro-2A). This model of engineered cell can be used in pharmaceutical screening and for autism and for *in vivo* modelling of NBEA biochemistry. It can be used as an assay, automated  
5 assay or high through put screening assay for identifying agents, compounds or chemical signals that directly or indirectly affect the biochemistry of NBEA, comprising the steps of: growing the cells in appropriate media, said cells comprising an introduced polynucleotide or DNA sequence, an allelic variant, minigene or a homologue thereof, that encodes for NBEA, NBEA isoforms or functional homologues thereof and expresses or overexpresses NBEA or  
10 functional homologues thereof, adding the test compound or chemical signal to the media; and measuring the extend to which the NBEA or functional homologues thereof or their function in the cell pathways are affected. NBEA maybe introduced in a cell that has been deleted for endogenous protein kinase (PKA).

15 The DNA sequence of present invention encoding and capable of expressing a neurobeachin or a BEACH-domain containing protein family with a protein kinase A binding domain such as the mammalian LBA will be capable, directly or indirectly, of modulating (e.g. the phosphorylation) of endogenous proteins or introduced proteins, can or may be introduced to establish or bring about a production in cell of the chosen protein kinase A-anchoring protein  
20 (AKAP) such as neurobeachin.

The invention includes also the progeny and all subsequent generations of the cells into which the said DNA sequence(s) were introduced.

25 This model of engineered cell (yeast or cell-lines) can be used in pharmaceutical screening for agents and for *in vivo* modelling of mammalian AKAPs and/or BEACH proteins, preferably neurobeachin biochemistry. It can be used as an assay, automated assay or high through put screening assay for identifying agents, compounds or chemical signals that directly or indirectly affect the biochemistry of neurobeachin and in particular of its binding capacity to  
30 protein kinase A or to MARCKS, comprising the steps of: growing the cell line in appropriate media, said cell comprising an introduced polynucleotide or DNA sequence, an allelic variant, minigene or a homologue thereof, that encodes for neurobeachin, neurobeachin isoforms or functional homologues thereof and expresses or overexpresses neurobeachin or functional

homologues thereof and wherein said cell comprising a protein that is capable directly or indirectly of being modulated by said neurobeachin and adding the test compound or chemical signal to the media; and measuring the extend to which neurobeachin or functional homologues thereof are affected.

5

Another aspect of the present invention is thus to provide insight in or a research tool to provide insight in a cellular pathway in which NBEA functions, which, when disrupted or altered, may result in a susceptibility or may cause autism in humans.

10 The present invention also provides a method and/or kit of screening for autism in a subject, comprising detecting either loss of function (all or part of) of any direct partner of NBEA (PKA, members of the MARCKS protein family, and the like), as well as any protein of the pathway in which NBEA functions (PKC, and the like) or the presence or absence of a mutation or a polymorphism in the corresponding encoding gene.

15

Since the *Drosophila melanogaster* DAKAP550 protein (of the BEACH protein family) is closely related to neurobeachin (about 50% similarity), *D. melanogaster* can be used as an animal model that permits study of the etiology of autism disease and provides a tool to identify new genes involved in the disease pathway, and to identify compounds that may be  
20 used to treat or alter the disease progression, lessen its severity or ameliorate symptoms. *D. melanogaster* can be used to investigate the neurobeachin pathway and the effect of deleted expression, decreased expression or overexpression of the DAKAP550 protein or of introduced neurobeachin to neuronal biochemistry and brain development of the fly. By correlating the phenotype of flies with wild-type DAKAP550 gene or defects in the DAKAP550 gene, or the  
25 phenotype of flies with wild type neurobeachin transgenes and or with defected NBEA transgenes, can be used to identify other genes involved in this pathway and also means for direct screening for lead candidate compounds for drugs for treatment of autism. Identification of additional genes necessary for neurobeachin or DAKAP550 function can provide additional diagnostic tools for autism. Flies can be mutagenized or treated with a test compound, and  
30 those that exhibit a change in phenotype can be identified. If test compounds or mutations responsible for the change in phenotype (possibly changes in behaviors) are identified, such compounds are candidates for the treatment of autism. Constructs, vectors, plasmids and *D. melanogaster* strains for comprising the transgene nucleic molecules of neurobeachin are



currently available for the man skilled in the art.

The detection step for assessing the function or for the presence or absence of a mutation or a polymorphism can be carried out as described above for the neurobeachin protein, mRNA and  
5 gene. Also, influencing this pathway through chemical compounds provides a potential treatment strategy for autism.

The present invention also concerns the creation by stereotactic lentiviral vector mediated gene transfer of non-human animals with locoregional transgenes of neurobeachin or close members  
10 of the BEACH-domain protein family to obtain autism models in non-human animals. More preferably this method involves stereotactic lentiviral vector mediated gene transfer in the brain of various non-human animal species. In its most preferred embodiment the method of this invention involves stereotactic lentiviral vector mediated gene transfer in the brain of rodents (mice, rat).

15

Yet another method aspect of the invention is a method and/or kit to create subjects with locoregional transgenes of neurobeachin (NBEA) or mutants thereof or to create disease models in non-human animals using stereotactic lentiviral vector mediated transfer of neurobeachin gene in the brain to overexpress or prevent expression of wild type or mutant  
20 neurobeachin gene or functional derivatives thereof or other autism associated genes. Animals with locoregional transgene neurobeachin gene or of autism models in non-human animals by locoregional transgene neurobeachin gene using stereotactic lentiviral vector mediated gene transfer in the brain to overexpress or prevent expression of disease associated genes involved in autism, may be used as animal models of autism.

25

One aspect of the invention is thus subjects and non-human animals harboring in their neural tissue or brains preferably in the cerebellum a transgene polynucleotide sequence, an allelic variant or a homologue thereof, that encodes for neurobeachin transgene or functional homologues thereof and overexpresses neurobeachin transgene, isoform of neurobeachin or  
30 functional homologues thereof locoregional in said neural tissue or said brains for used a therapeutic treatment of autism or as a disease model of autism. Lentiviral vector mediated transfer of neurobeachin gene or functional derivatives thereof may also be used in a transfer to the bari of a subject or as a treatment of autism.

Transgenes comprising the neurobeachin gene an allelic variant, minigene, a homolog thereof, that encode for neurobeachin, an isoform of neurobeachin or functional homologues thereof or at least a portion thereof, are obtainable by a method comprising 1) producing HIV-1-derived vector particles, pseudotyped with the envelope of non related virus, said HIV-1 derived vector particles obtainable by transfecting suitable cells in suitable agents with a suitable packaging plasmid encoding viral gag and pol proteins, a plasmid encoding the envelope of a non related virus and a plasmid encoding neurobeachin gene or an allelic variant, minigene or a homolog thereof which is flanked by LTR's, 2) isolating and concentrating the vector particles 3) redissolving the vector particles in a suitable agent, 4) injecting the vector particle solution in stereotactically defined targets of the brain of a subject. Pharmaceutical compositions in a pharmaceutically acceptable carrier in the created animal models maybe administered (systemically or locally) and verifying whether the compound alters expression of transgene neurobeachin qualitatively or quantitatively and/or alters the observed pathology or behaviours. Such pharmaceutical compositions should contain a therapeutic amount of at least one compound identified by the method of the present invention. Such compound may be a nucleic acid encoding a protein or fragment of a protein. The pharmaceutically acceptable carrier can be any compatible, non-toxic substance suitable to deliver the compounds to an intended host, animal host or cell line. Sterile water, alcohol, fats, waxes, and inert solids may be used as the carrier. Pharmaceutically acceptable adjuvants, buffering agents, dispersing agents, and the like may also be incorporated into the pharmaceutical compositions. Preparation of pharmaceutical conditions incorporating active agents is well described in the medical and scientific literature (See, for example, Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pa., 16th Ed., 1982, the disclosure of which is incorporated herein by reference). The pharmaceutical compositions just described are suitable for injection in targeted zones and regions of the brain or neural tissue. Thus, the present invention provides compositions for administration to an animal host, where the compositions comprise a pharmaceutically acceptable solution of the identified compound in an acceptable carrier, as described above.

It is an object of the present invention to provide a method for diagnosing and prognosing a neural tissue of a human.

It is another object of the invention to provide a method of supplying wild-type NBEA gene

function to a cell which has lost said gene function.

It is yet another object of the invention to provide a kit for determination of the nucleotide sequence of the NBEA gene by the polymerase chain reaction.

It is still another object of the invention to provide nucleic acid probes for detection of mutations in the human NBEA gene.

It is another object of the invention to provide a method of detecting genetic predisposition to autism.

It is still another object of the invention to provide a cDNA molecule encoding the NBEA gene product for use in a kit or for manufacturing a kit to diagnose autism.

It is still another object of the invention to provide a cDNA molecule encoding the NBEA gene product for use in a medicament or to manufacture a medicament to treat autism.

It is still another object of the invention to provide a cDNA molecule encoding the NBEA gene product for use in a kit or to manufacture a kit to transfer NBEA gene in cells.

It is yet another object of the invention to provide a preparation of the human NBEA protein.

These and other objects of the invention are provided by one or more of the embodiments which are described below. In one embodiment of the present invention a method is provided of diagnosing or prognosing one or more cells, preferably tissue and more preferably neural tissue of a human, comprising:

isolating a cell or tissue from a human;

detecting loss of wild-type NBEA gene coding sequences or their expression products from said cell or tissue, said loss indicating autism.

In another embodiment of the present invention a method is provided for supplying wild-type NBEA function to a cell which has lost said gene function by virtue of mutation in a NBEA gene, comprising:

introducing a wild-type NBEA gene into a cell which has lost said gene function such that said transgene is expressed in the cell.

In another embodiment a method of supplying wild-type NBEA gene function to a cell which has lost said gene function by virtue of a mutation in a NBEA gene, comprising:  
introducing a portion of a wild-type NBEA gene into a cell which has lost said gene function

such that said portion is expressed in the cell, said portion encoding a part of the NBEA protein which is required for normal function of said cell.

5 In yet another embodiment a kit is provided for determination of the nucleotide sequence of a NBEA gene by polymerase chain reaction, comprising:  
sets of pairs of single stranded DNA primers, said sets allowing synthesis of all nucleotides of the NBEA gene coding said wild-type NBEA gene.

10 In still another embodiment of the invention a nucleic acid probe is provided which is complementary to human wild-type NBEA gene coding sequences and which can form mismatches with mutant NBEA genes, thereby allowing their detection by enzymatic or chemical cleavage or by shifts in electrophoretic mobility.

15 In another embodiment a particular nucleic acid probe is provided which hybridizes to a NBEA intron which is subject to insertional mutations in its neural cells.

In yet another embodiment a method is provided of detecting genetic predisposition to autism in a human comprising:  
isolating human sample from neural tissue, or any tissue expressing neurobeachin;  
20 detecting loss of wild-type NBEA gene coding sequences or their expression products from the sample, said loss indicating predisposition to autism.

In still other embodiments a cDNA molecule comprising a coding sequence of the NBEA gene.

25 In even another embodiment a preparation of the human NBEA protein is provided which is substantially free of other human proteins for use as a medicine, for use to manufacture a medicine or for use in the prophylactic or therapeutic treatment of autism

30 In yet another embodiment a preparation of the human NBEA protein is provided which is substantially free of other human proteins for use in a diagnostic kit, or for use to manufacture a diagnostic kit for autism.

## Brief Description of the Drawings

This application includes Figures 1-7

- 5 Figure 1. FISH analysis of metaphase chromosomes of VC cells of the autistic patient using cosmid clone 25I17. Hybridization signals are marked by arrows with a chromosome identity label

- 10 Figure 2 . Map of the breakpoint (BP) region in the autistic patient. (A) FISH analysis. At the BAC level, clone 307O13 is proximal and 66B8 distal to the BP. At the level of cosmids (obtained by cosmid library screening with 66B8\_probe2, 6 and 8, cosmids 32G24 and 7H10 are proximal, and 4B16 is distal to the BP. Cosmids 25I17 and 27F13 span the BP. (B) Restriction map used for Southern blot analysis (Fig. 4) with 66B8\_South probe; the BP is narrowed down to a 2.8 kb *HindIII/BamHI* restriction fragment.

15

- Figure 3 . Southern blot analysis of genomic DNA from the autistic patient (P) and a control individual (C). Genomic DNA was digested with the mentioned restriction enzymes. Using probe 66B8\_South, rearranged fragments are observed for the *EcoRI* (5.9 kb), *HindIII* (8.7 kb) and *PstI* (11.5 kb) digestions in the patient, in addition to the 8.0 kb, 6.4 kb and 14.7 kb wild type fragments, respectively. In the control, only the wild type fragment is visible.
- 20

- Figure 4. Expression pattern of the hNbea transcript. Northern blots of total RNA from human tissues (Clontech). The probe used for hybridization is hNbea-ex56. Tissue abbreviations are as followed: B, brain; H, heart; K, kidney; L, liver; Lu, lung; P, pancreas; Pl, placenta; S, skeletal muscle.
- 25

- Figure 5. Expression of Neurobeachin in mouse embryos. Whole mount *in situ* hybridizations of developing embryos. (A) Ubiquitous expression at stage E7.5. (B) Expression in the limbs, the tail, the branchial arches, and the nose at stage E10.5.

30

- Figure 6. Expression of Neurobeachin in the hippocampus of adult mouse. (A) *In situ* hybridization. (B) Immunohistochemistry.

Figure 7. Expression of Neurobeachin in the cerebellum of adult mouse. (A) *In situ* hybridization. (B) Immunohistochemistry.

## 5 Detailed Description of Preferred Embodiments

Generally, the nomenclature used hereafter and the laboratory procedures in cell culture, molecular genetics, and nucleic acid chemistry and hybridisation described below are those well known and commonly employed in the art. All nucleotide sequences shown herein are presented from the 5' to the 3' direction. Standard nucleotide abbreviations are used. Except as otherwise indicated, standard techniques may be used for histology, polynucleotide synthesis, cell culture, production and manipulation of cloned genes, vectors, transformed cells (and cell culture) and recombinant DNA technology according to the present invention. Such techniques are known to those skilled in the art (see *e.g.*, SAMBROOK *et al.*, EDS., MOLECULAR CLONING: A LABORATORY MANUAL 2d ed. (Cold Spring Harbor, NY 1989); F.M. AUSUBEL *et al.*, EDS., CURRENT PROTOCOLS IN MOLECULAR BIOLOGY (Green Publishing Associates, Inc. and John Wiley & Sons, Inc., New York).

Generally, enzymatic reactions oligonucleotide synthesis, and purification steps are performed according to the manufacturer's specifications. The techniques and procedures of stereotactic surgery are generally performed according to conventional methods in the art and various general references which are provided throughout this document. The procedures therein are believed to be well known in the art and are provided for the convenience of the reader. All the information contained therein is incorporated herein by reference. Unique technologies are detailed and explained in the examples.

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are described. For purposes of the present invention, the following terms are defined below.

The term "non-dividing cell" used herein means animal cells such as nerve, liver, muscle and bone marrow stem cells.

5 The term "Transgene" means any piece of DNA which can be inserted into a cell, and preferably becomes part of the genome of the resulting organism (i.e. either stably integrated or as a stable extrachromosomal element). Such a transgene includes genes which are partly or entirely heterologous (i.e. foreign) as well as genes homologous to endogenous genes of the organism. Including within this definition is a transgene created by providing an RNA sequence which is reverse transcribed into DNA and then incorporated into the genome, or an  
10 antisense agent or molecule.

The term "animal" herein is used to mention non-human animals.

15 The term "transgenic animal" is used herein to mention non-human animals, having a non-endogenous (i.e. heterologous) nucleic acid sequence present as a extrachromosomal element in stably integrated into its germ line DNA (i.e. in the genomic DNA of most or all of its cells). Heterologous nucleic acid is introduced into the germ line of such transgenic animals by genetic manipulation of, for example, embryous or embryonic stem cells of the host animal. A "transgenic" animal is any animal containing cells that bear genetic information received,  
20 directly or indirectly, by deliberate genetic manipulation at the subcellular level

The term "animals with locoregional neural transgenes" is used herein to mean non-human animals which overexpresses a exogenous peptide, polypeptide or protein or at least a portion thereof in at least one precisely localised region in the brain or other neural tissue after local  
25 delivery, preferably stereotactic vector-mediated transfer, of a "heterologous gene" or "heterologous polynucleotide sequence" encoding a exogenous peptide, polypeptide or protein or at least a portion thereof.

30 The term "locoregional transgenic brains" is used herein to mean brains of non-human animals which overexpresses a exogenous peptide, polypeptide or protein or at least a portion thereof in at least one precisely localised region in the brain or other neural tissue after local delivery, preferably stereotacted vector-mediated transfer, of a "heterologous gene" or "heterologous polynucleotide sequence" encoding a exogenous peptide, polypeptide or protein or at least a

portion thereof.

The term "vector" is used herein to mean that a DNA molecule, derived, e.g., from a plasmid or virus, into which fragments of DNA may be inserted or cloned. A vector will contain one or more unique restriction sites and may be capable of autonomous replication in a defined host or vehicle organism such that the cloned sequence is reproducible.

The term "antisense agent" refers to a molecule which interacts directly with intracellular DNA or RNA to achieve a therapeutic effect. Examples of antisense agents include, without limitation, DNA-binding molecules, triple-helix (or triplex) forming agents, ribozymes, and the like. Antisense agents may be prepared from naturally-occurring nucleotides, or may contain modified bases.

As used herein, a "heterologous gene" or "heterologous polynucleotide sequence" is defined in relation to humans or to the animals with locoregional neural transgenes producing such a gene product in targeted zones or regions of the brain or neural tissue. A heterologous polypeptide, also referred to as a xenogenic polypeptide, is defined as a polypeptide having an amino acid sequence or an encoding DNA sequence corresponding to that of a cognate gene found in an organism not consisting of the animals which harbored the locoregional neural transgenes. Thus, a human or an animal with locoregional expression in brains or neural tissue of a neurobeachin gene can be described as harbouring a heterologous neurobeachin gene. A cognate heterologous gene refers to a corresponding gene from another species; thus human neurobeachin is a cognate heterologous gene for mice. A mutated endogenous gene sequence can be referred to as a heterologous gene.

25

The term "yeast cell" herein is used to mention single-celled fungi of the phylum Ascomycota that reproduce by fission or budding and are capable of fermenting carbohydrates into alcohol and carbon dioxide. Yeast cells of the species *Saccharomyces cerevisiae* are preferred for manipulation to incorporate DNA sequences in accordance with the present invention. Such cells do not normally express a mammalian neurobeachin but are capable of expressing human neurobeachin by introduction of a DNA sequence encoding neurobeachin under the control of appropriate regulatory DNA sequences. The resulting DNA sequence is considered a



"recombinant" DNA sequence or a "transgene".

The term "engineered yeast" is used herein to mention yeast cells, having a transgene or non-endogenous (i.e. heterologous) nucleic acid sequence present as a extrachromosomal element  
5 in stably integrated into its germ line DNA (i.e. in the genomic DNA). Heterologous nucleic acid is introduced into the germ line of such engineered by genetic manipulation

The term "introduced DNA sequence" is used herein to denote a DNA sequence that has been introduced into a cell and which may or may not be incorporated into the genome. The DNA  
10 sequence may be a sequence that is not endogenous to the chosen type of cell, that is endogenous but is not normally expressed by that cell or that is endogenous and is normally expressed but of which over-expression is desired. The DNA sequence may be introduced by any suitable transfection technique including electroporation, calcium phosphate precipitation, lipofection or other known to those skilled in the art. The sequence may have been introduced  
15 directly into the cell or may have been introduced into an earlier generation of the cell.

As used herein, the term "minigene" refers to a heterologous gene construct wherein one or more nonessential segments of a gene are deleted with respect to the naturally-occurring gene. Typically, deleted segments are intronic sequences of at least about 100 basepairs to several  
20 kilobases, and may span up to several tens of kilobases or more. Isolation and manipulation of large (i.e., greater than about 50 kilobases) targeting constructs is frequently difficult and may reduce the efficiency of transferring the targeting construct into a host cell. Thus, it is frequently desirable to reduce the size of a targeting construct by deleting one or more nonessential portions of the gene. Typically, intronic sequences that do not encompass essential  
25 regulatory elements may be deleted. Frequently, if convenient restriction sites bound a nonessential intronic sequence of a cloned gene sequence, a deletion of the intronic sequence may be produced by: (1) digesting the cloned DNA with the appropriate restriction enzymes, (2) separating the restriction fragments (e.g., by electrophoresis), (3) isolating the restriction fragments encompassing the essential exons and regulatory elements, and (4) ligating the  
30 isolated restriction fragments to form a minigene wherein the exons are in the same linear order as is present in the germline copy of the naturally-occurring gene. Alternate methods for producing a minigene will be apparent to those of skill in the art (e.g., ligation of partial genomic clones, which encompass essential exons but which lack portions of intronic

sequence). Most typically, the gene segments comprising a minigene will be arranged in the same linear order as is present in the germline gene, however, this will not always be the case. Some desired regulatory elements (e.g., enhancers, silencers) may be relatively position-insensitive, so that the regulatory element will function correctly even if positioned differently in a minigene than in the corresponding germline gene. For example, an enhancer may be located at a different distance from a promoter, in a different orientation, and/or in a different linear order. For example, an enhancer that is located 3' to a promoter in germline configuration might be located 5' to the promoter in a minigene. Similarly, some genes may have exons, which are alternatively spliced, at the RNA level, and thus a minigene may have fewer exons and/or exons in a different linear order than the corresponding germline gene and still encode a functional gene product. A cDNA encoding a gene product may also be used to construct a minigene. However, since it is often desirable that the heterologous minigene be expressed similarly to the cognate naturally-occurring non-human gene, transcription of a cDNA minigene typically is driven by a linked gene promoter and enhancer from the naturally-occurring gene. Frequently, such minigene may comprise a transcriptional regulatory sequence (e.g., promoter and/or enhancer) that confers neuron-specific or CNS-specific transcription of the neurobeachin encoding sequences.

The term "agent" is used herein to denote a chemical compound, a mixture of chemical compounds, a biological macromolecule, or an extract made from biological materials such as bacteria, plants, fungi, or animal (particularly mammalian) cells or tissues.

The term "autism" as used herein has its conventional meaning in the art (see, e.g., U.S. Patents Nos. 5,686,311 and 5,405,943) (applicants specifically intend that all U.S. Patent references cited herein be incorporated herein by reference). In general, autism is a pervasive developmental disorder involving language delay and dysfunction in reciprocal social interaction, and includes a spectrum of disorders that may or may not involve mental deficit or retardation. Thus, high functioning individuals (i.e., individuals with normal intelligence) may be afflicted with autism. Autism is typically considered a life-long disorder, and thus may be present in infant, juvenile, adolescent and adult subjects. Mammalian subjects are preferred, with human subjects being more preferred. The subjects may be male or female, but are preferably male subjects, more preferably, human male subjects.

The mouse neurobeachin cDNA (mNbea) and the corresponding protein (mNBEA) are known (Wang, X., *et al.* J. Neurosci. 20 (23), 8551-8565 (2000)) DBSOURCE Accession Number Y18276.1; see also "The neurobeachin gene (Nbea) identifies a new region of homology between mouse central chromosome 3 and human chromosome 13q13" (Gilbert, D.J. Mamm. Genome 10 (10), 1030-1031 (1999)). The full-length cDNA sequence of the human orthologue of neurobeachin is known DBSOURCE Accession Number AF467288 or NM\_015678.

Oligonucleotide probes that specifically bind to an NBEA DNA or RNA that contains a mutation or a polymorphism, but do not bind to a NBEA DNA or RNA that does not contain the mutation or polymorphism, may be produced in accordance with known techniques. Such probes are typically from 5 or 10 nucleotides in length to 20, 30 or 50 nucleotides in length or more. Such probes may be natural or synthetic.

As noted above, the present invention provides a method of screening (e.g., diagnosing or prognosing) for autism in a subject (typically, a human subject). The method comprises detecting the presence or absence of a mutation or a polymorphism in the subject. The presence of such a mutation indicates that the subject is afflicted with autism or is at risk of developing autism. Suitable subjects include those which have not previously been diagnosed as afflicted with autism, those which have previously been determined to be at risk of developing autism, and those who have been initially diagnosed as being afflicted with autism where confirming information is desired. Thus, subjects may be of any age, including adult, adolescent, juvenile, infant, and even prenatal or *in utero* subjects. Preferably, the subjects are male subjects.

Affliction with autism is more likely if a mutation described above is present. A subject with the mutation has increased risk of developing autism over subjects in which the mutation is absent. A subject who is "at increased risk of developing autism" is one who is predisposed to the disease, has genetic susceptibility for the disease or is more likely to develop the disease than subjects in which the mutation is absent.

Further, the methods of the present invention can be used to aid in determining the prognosis of a subject afflicted with or at risk for autism based on the observation of how many alleles containing the mutation are detected in the subject. The subject's prognosis is more negative if the presence of the mutation is detected than if it is absent. In particular embodiments, the subject's prognosis is most negative if the presence of more than one allele containing the mutation is detected (i. e., if the subject is homozygous as opposed to heterozygous). In other

embodiments, homozygous subjects do not appear to be at a substantially higher risk than heterozygous subjects.

It is contemplated that the methods described herein be used in conjunction with other clinical diagnostic information known or described in the art that are used in the evaluation of subjects with autism or suspected to be at risk for developing such disease.

The step of detecting a mutation or a polymorphism may be carried out either directly or indirectly by any suitable means. A variety of techniques are known to those skilled in the art. All generally involve the step of collecting a sample of biological material containing DNA, and then detecting whether or not the subject possesses DNA containing such a mutation from that sample.

Any biological sample that contains the nucleic acid (e.g., DNA, RNA) of that subject may be employed, including tissue samples and blood samples, with blood cells being a particularly convenient source.

Determining the presence or absence of nucleic acid containing a mutation or a polymorphism may be carried out with an oligonucleotide probe labeled with a suitable detectable group, or by means of an amplification reaction such as a polymerase chain reaction or ligase chain reaction (the product of which amplification reaction may then be detected with a labeled oligonucleotide probe or a number of other techniques). Further, the detecting step may include the step of detecting whether the subject is heterozygous or homozygous for a mutation or a polymorphism.

Amplification of a selected, or target, nucleic acid sequence may be carried out by any suitable means. See generally D. Kwoh and T. Kwoh, *Am. Biotechnol. Lab.* 8, 14-25 (1990). Examples of suitable amplification techniques include, but are not limited to, polymerase chain reaction (see generally G. Walker *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* 89,392-396 (1992); G. Walker *et al.*, *Nucleic Acids Res.* 20, 1691-1696 (1992)), transcription-based amplification (see D. Kwoh *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* 86, 1173-1177 (1989)). Polymerase chain reaction (PCR) may be carried out in accordance with known techniques. See, e.g., U.S. Pat. Nos. 4,683,195; 4,683,202; 4,800,159; and 4,965,188. In general, PCR involves, first, treating a nucleic acid sample (e.g., in the presence of a heat stable DNA polymerase) with one oligonucleotide primer for each strand of the specific sequence to be detected under

hybridizing conditions so that an extension product of each primer is synthesized which is complementary to each nucleic acid strand, with the primers sufficiently complementary to each strand of the specific sequence to hybridize therewith so that the extension product synthesized from each primer, when it is separated from its complement, can serve as a  
5 template for synthesis of the extension product of the other primer, and then treating the sample under denaturing conditions to separate the primer extension products from their templates if the sequence or sequences to be detected are present.

Kits for determining if a subject is or was afflicted with or is or was at increased risk of  
10 developing autism will include at least one reagent specific for detecting for the presence or absence of a mutation or polymorphism, and instructions for observing that the subject is or was afflicted with or is or was at increased risk of developing autism if the presence of the mutation is detected. The kit may optionally include a nucleic acid or oligonucleotide probe for detection of the mutation in a manner such as described above. The test kit may be packaged in  
15 any suitable manner, typically with all elements in a single container or package along with a sheet of printed instructions for carrying out the test.

An isolated DNA as described above may be provided in a suitable vector, including but not limited to plasmids, viral vectors, yeast artificial chromosomes, bacterial artificial  
20 chromosomes, naked DNA vectors, and the like. Preferably, the vector is a plasmid. The present invention also provides cells that have been transformed with the vector, and preferably express the DNA therein. Cells according to the present invention may be any suitable cells for replicating and expressing the DNA, including but not limited to bacterial cells, yeast cells, plants cells, and animal cells (e.g., avian, insect and mammalian cells). Mammalian (e.g.,  
25 human, mouse, rat, canine, simian), insect and bacterial cells are preferred. Such cells may be grown in cell culture using standard techniques. The cells of the invention may be used to screen new oligonucleotide probes for use in the diagnostic and prognostic techniques described above. In addition, such cells may be used to screen for compounds that affect the mutations described herein, which compounds are then candidate compounds for treating  
30 autism.

According to the diagnostic and prognostic method of the present invention, loss of the wild-type gene is detected. The loss may be due to either insertional, deletional or point mutational

events. The finding of NBEA mutations thus provides both diagnostic and prognostic information.

A NBEA allele which is not deleted (e.g., that on the sister chromosome to a chromosome carrying a NBEA deletion) can be screened for other mutations, such as insertions, small deletions, and point mutations.

Detection of point mutations may be accomplished by molecular cloning of the allele (or alleles) present in the neural tissue of test subject and sequencing that allele(s) using techniques well known in the art. Alternatively, the polymerase chain reaction can be used to amplify gene sequences directly from a genomic DNA preparation from neural tissue. The DNA sequence of the amplified sequences can then be determined. The polymerase chain reaction itself is well known in the art. See, e.g., Saiki *et al.*, Science, Vol. 239, p. 487, 1988; U.S. 4,683,203; and U.S. 4,683,195. Specific primers which can be used in order to amplify the gene will be discussed in more detail below. Insertions and deletions of genes can also be detected by these techniques. In addition, restriction fragment length polymorphism (RFLP) probes for the gene or surrounding marker genes can be used to score loss of an allele or an insertion in a polymorphic fragment. Other techniques for detecting insertions and deletions as are known in the art can be used.

Loss of wild-type genes can also be detected on the basis of the loss of a wild-type expression product of the gene. Such expression products include both the mRNA as well as the protein product itself. Point mutations may be detected by amplifying and sequencing the mRNA or via molecular cloning of cDNA made from the mRNA. The sequence of the cloned cDNA can be determined using DNA sequencing techniques which are well known in the art.

Mismatches, according to the present invention are hybridized nucleic acid duplexes which are not 100% homologous. The lack of total homology may be due to deletions, insertions, substitutions or frameshift mutations. Mismatch detection can be used to detect point mutations in the gene or its mRNA product. An example of a mismatch cleavage technique is the RNase protection method, which is described in detail in Winter *et al.*, Proc. Natl. Acad. Sci. USA, Vol. 82, p. 7575, 1985 and Meyers *et al.*, Science, Vol. 230, p. 1242, 1985. In the practice of the present invention the method involves the use of a labeled riboprobe which is

complementary to the human wild-type gene coding sequence. The riboprobe and either mRNA or DNA isolated from the neural tissue are annealed (hybridized) together and subsequently digested with the enzyme RNase A which is able to detect some mismatches in a duplex RNA structure. If a mismatch is detected by RNase A, it cleaves at the site of the mismatch. Thus, when the annealed RNA preparation is separated on an electrophoretic gel matrix, if a mismatch has been detected and cleaved by RNase A, an RNA product will be seen which is smaller than the full-length duplex RNA for the riboprobe and the mRNA or DNA. The riboprobe need not be the full length of the NBEA mRNA or gene but can be a segment of either. If the riboprobe comprises only a segment of the NBEA mRNA or gene it will be desirable to use a number of these probes to screen the whole mRNA sequence for mismatches.

In similar fashion, DNA probes can be used to detect mismatches, through enzymatic or chemical cleavage. See, e.g., Cotton *et al.*, Proc. Natl. Acad. Sci. USA, vol. 85, 4397, 1988; and Shenk *et al.*, Proc. Natl. Acad. Sci. USA, vol. 72, p. 989, 1975. Alternatively, mismatches can be detected by shifts in the electrophoretic mobility of mismatched duplexes relative to matched duplexes. See, e.g., Cariello, Human Genetics, vol. 42, p. 726, 1988. With either riboprobes or DNA probes, the cellular mRNA or DNA which might contain a mutation can be amplified using PCR (see below) before hybridization. Changes in DNA of the NBEA gene can also be detected using Southern hybridization, especially if the changes are gross rearrangements, such as deletions and insertions.

20

DNA sequences of the NBEA gene from neural tissue which have been amplified by use of polymerase chain reaction may also be screened using allele-specific probes. These probes are nucleic acid oligomers, each of which contains a region of the NBEA gene sequence harboring a known mutation. For example, one oligomer may be about 30 nucleotides in length, corresponding to a portion of the NBEA gene sequence. By use of a battery of such allele-specific probes, the PCR amplification products can be screened to identify the presence of a previously identified mutation in the NBEA gene. Hybridization of allele-specific probes with amplified NBEA sequences can be performed, for example, on a nylon filter. Hybridization to a particular probe under stringent hybridization conditions indicates the presence of the same mutation in the neural tissue as in the allele-specific probe.

30

Loss of NBEA mRNA expression can be detected by any technique known in the art. These include Northern analysis, PCR amplification and RNase protection. Diminished mRNA

expression indicates a loss of the wild-type NBEA gene.

Loss of wild-type NBEA genes can also be detected by screening for loss of wild-type NBEA protein. For example, monoclonal antibodies immunoreactive with NBEA can be used to  
5 screen a tissue. Lack of antigen would indicate a NBEA mutation. Antibodies specific for mutant alleles could also be used to detect mutant NBEA gene product. Such immunological assays could be done in any convenient format known in the art. These include Western blots, immunohistochemical assays and ELISA assays. Any means for detecting an altered NBEA protein can be used to detect loss of wild-type NBEA genes. Finding a mutant NBEA gene  
10 product indicates loss of a wild-type NBEA gene.

Mutant NBEA genes or gene products can possibly be detected in other human body samples than neural tissue. The same techniques discussed above for detection of mutant NBEA genes or gene products in neural tissues can be applied to other body samples. In addition, the NBEA  
15 gene product itself may be secreted into the extracellular space and found in these body samples. By screening such body samples, a simple early diagnosis can be achieved for autism detection.

The diagnostic method of the present invention is useful for clinicians so that they can decide  
20 upon an appropriate course of treatment.

The primer kit of the present invention is useful for determination of the nucleotide sequence of the NBEA gene using the polymerase chain reaction. The kit comprises a set of pairs of single stranded DNA primers which can be annealed to sequences within or surrounding the  
25 NBEA gene in order to prime amplifying DNA synthesis of the NBEA gene itself. The complete set allows synthesis of all of the nucleotides of the NBEA gene coding sequences, i.e., the exons. The set of primers can also allow synthesis of both intron and exon sequences, to include NBEA mutations in the NBEA introns. The kit can also contain DNA polymerase, preferably Taq polymerase, and suitable reaction buffers. Such components are  
30 known in the art.

In order to facilitate subsequent cloning of amplified sequences, primers may have restriction enzyme sites appended to their 5' ends. Thus, all nucleotides of the primers are derived from



NBEA sequences or sequences adjacent to NBEA except the few nucleotides necessary to form a restriction enzyme site. Such enzymes and sites are well known in the art. The primers themselves can be synthesized using techniques which are well known in the art. Generally, the primers can be made using synthesizing machines which are commercially available. Given the sequence of the NBEA open reading frame, design of particular primers is well within the skill of the art.

The nucleic acid probes provided by the present invention are useful for a number of purposes. They can be used in Southern hybridization to genomic DNA and in the RNase protection method for detecting point mutations already discussed above. The probes can be used to detect PCR amplification products. They may also be used to detect mismatches with the NBEA gene or mRNA using other techniques. Mismatches can be detected using either enzymes (e.g., S1 nuclease), chemicals (e.g., hydroxylamine or osmium tetroxide and piperidine), or changes in electrophoretic mobility of mismatched hybrids as compared to totally matched hybrids. These techniques are known in the art. See, Cotton, supra, Shenk, supra, Myers, supra, Winter, supra, and Novack *et al.*, Proc. Natl. Acad. Sci. USA, vol. 83, p. 586, 1986. Generally, the probes are complementary to NBEA gene coding sequences, although probes to certain introns are also contemplated. An entire battery of nucleic acid probes can be used to compose a kit for detecting loss of wild-type NBEA genes, the kit allowing for hybridization to the entire NBEA gene. The probes may overlap with each other or be contiguous.

If a riboprobe is used to detect mismatches with mRNA, it is complementary to the mRNA of the human wild-type NBEA gene. The riboprobe thus is an anti-sense probe in that it does not code for the NBEA protein because it is of the opposite polarity to the sense strand. The riboprobe generally will be radioactively labeled which can be accomplished by any means known in the art. If the riboprobe is used to detect mismatches with DNA it can be of either polarity, sense or anti-sense. Similarly, DNA probes also may be used to detect mismatches. Nucleic acid probes may also be complementary to mutant alleles of NBEA gene. These are useful to detect similar mutations in other patients on the basis of hybridization rather than mismatches. These are discussed above and referred to as allele-specific probes. As mentioned above, the NBEA probes can also be used in Southern hybridizations to genomic DNA to detect gross chromosomal changes such as deletions and insertions. The probes can also be

used to select cDNA clones of NBEA genes from neural tissues from autistic subjects and from normal neural tissues. In addition, the probes can be used to detect NBEA mRNA in tissues to determine if expression is diminished as a result of loss of wild-type NBEA genes. Provided with the NBEA coding sequence, design of particular probes is well within the skill of the  
5 ordinary artisan.

According to the present invention a method is also provided of supplying wild-type NBEA function to a cell which carries mutant NBEA alleles. The wild-type NBEA gene or a part of the gene may be introduced into the cell in a vector such that the gene remains  
10 extrachromosomal. In such a situation the gene will be expressed by the cell from the extrachromosomal location. If a gene portion is introduced and expressed in a cell carrying a mutant NBEA allele, the gene portion should encode a part of the NBEA protein which is required for normal functioning of the cell. More preferred is the situation where the wild-type NBEA gene or a part of it is introduced into the mutant cell in such a way that it recombines  
15 with the endogenous mutant NBEA gene present in the cell. Such recombination requires a double recombination event which results in the correction of the NBEA gene mutation. Vectors for introduction of genes both for recombination and for extrachromosomal maintenance are known in the art and any suitable vector may be used. Methods for introducing DNA into cells such as electroporation, calcium phosphate co-precipitation and  
20 viral transduction are known in the art and the choice of method is within the competence of the routineer. Cells transformed with the wild-type NBEA-gene can be used as model systems to study autism related to the cellular dysfunction and drug treatments which promote the reinstatement of normal cellular functions.

25 Polypeptides which have NBEA function can be supplied to cells which carry mutant or missing NBEA alleles. The NBEA protein can be produced by expression of the cDNA sequence in bacteria or eukaryotic cells (yeast or CHO cells), for example, using known expression vectors. Alternatively, NBEA can be extracted from NBEA-producing mammalian cells such as brain cells or cell-lines (AtT-20 or Neuro-2A).  
30 The preparation is substantially free of other human proteins. This is most readily accomplished by synthesis in a microorganism or *in vitro*. Active NBEA molecules can be introduced into cells by microinjection or by use of liposomes, for example. Alternatively, some such active molecules may be taken up by cells, actively or by diffusion. The application

of NBEA gene product may be sufficient to restore normal cell function. Other molecules with NBEA activity may also be used to effect.

Predisposition to autism can be ascertained by testing neural tissues of humans for mutations of NBEA gene. For example, a person who has inherited a germline NBEA mutation would be prone to develop autism. This can be determined by testing DNA from tissue, preferably neural tissue of the person's body and most preferably from the central nervous system. In addition, prenatal diagnosis can be accomplished by testing fetal cells or amniotic fluid for mutations of the NBEA gene. Loss of a wild-type NBEA allele, whether for example, by point mutation or by deletion, can be detected by any of the means discussed above.

Molecules of cDNA according to the present invention are NBEA gene coding molecules, that can be made by reverse transcriptase using the NBEA mRNA as a template. These molecules can be propagated in vectors and cell lines as is known in the art. The cDNA can also be made using the techniques of synthetic chemistry given the sequence disclosed herein.

The present invention is explained in greater detail in the following non-limiting examples.

## 20 EXAMPLE 1

### Disruption of the NBEA-gene in a patient with autism

A detailed molecular genetic analysis of an autistic male, with a *de novo* balanced translocation t(5;13)(q13.3;q14.3) was completed. The patient has no severe mental retardation and none of his relatives exhibit symptoms of autism.

25 FISH analysis, by means of BACs hybridized against prometaphase chromosomes of the patient, was first used to delineate the rearrangement sites involved in the translocation event: clones RP11-307O13 (AL138690) and RP11-66B8 (AL161902) are proximal and distal to the breakpoint, respectively (data not shown). These clones overlap for 100 bp only and are part of the 10523-kb contig NT\_009984, for which the complete DNA sequence is known (GenBank accession number GI: 22052081). Cosmids corresponding to probes located within these BACs  
30 were isolated by cosmid library screening and used for FISH analysis. 25I17 cosmid, fished with 66B8-probe8 (primers: 66B8\_probe8S, 5'-CTGCCTGCTTCCCTGGATTCAG-3', 66B8\_probe8AS, 5'-ATGGTGCATGGCTCTCACAGAG AG-3'), was shown to span the

breakpoint on chromosome 13 (Fig. 1). The extremities of the cosmid clone were sequenced in order to map it on the breakpoint region (Fig.2).

Southern blot hybridization analysis with DNA from the patient and a normal control digested with various restriction enzymes revealed a 5.9 kb *EcoRI*, a 8.7 kb *HindIII* and a 11.5 kb *PstI* additional rearrangement fragments in the patient's genomic DNA (Fig. 3) when using 66B8-South probe (primers: 66B8\_South probe\_S, 5'-TCCATTTGTTTCATCACCCTTGTGG-3', 66B8\_South probe\_AS, 5'-CATGTAACAAGTCAATCTCCTCTTCCCC-3'), indicating that the breakpoint is located within a 2.8 kb *HindIII/BamHI* restriction fragment (Fig.2).

Database search analysis using BLAST (National Center for Biotechnology Information) revealed that neurobeachin is located in the vicinity of the chromosome 13q12 breakpoint. A blastn of the complete mouse cDNA neurobeachin sequence (10949 nt) against the human genome revealed homology along contig NT\_009984, corresponding to 58 exons of the human orthologue of neurobeachin, spanning 730 kb of the human genome; it is disrupted by the breakpoint on 13q12, in intron 2. Recently, the full cDNA sequence of the human NBEA(NM\_015678), also called *BCL8B* (AF467288) has been published in Genbank (GenBank accession number GI: 21536251 and 21434742, respectively).

## EXAMPLE 2

### Isolation of a full length NBEA cDNA

The full-length cDNA of the *NBEA* gene was cloned by RT-PCR. The sequence was assembled in a consensus transcript of 10812 nt in length, in full agreement with the published sequences. This sequence predicted a continuous open reading frame (ORF) of 8838 nt translated in a protein of 2946 aa. Moreover, a CpG island encompassing 1456 bp of *NBEA* was identified (<http://125.itba.mi.cnr.it/genebin/wwwcpgr.pl>). A putative promoter was also found within this region using the Promoter Inspector program (<http://genomatix.gsf.de/cgi-bin/>).

## EXAMPLE 3

### Preparation of rabbit antisera reactive with NBEA proteins from mouse and human

Standard protocol of rabbit immunization with peptides was used by Eurogentec to produce 3 antisera reactive with the human and the mouse native NBEA. The pure peptides were coupled to the Keyhole Limpet Hemocyanin carrier protein. The antisera are immunoreactive with NBEA epitopes not present on other human proteins. The antisera can immunoprecipitate

NBEA proteins from solution as well as react with NBEA protein on Western blots of polyacrylamide gels. The antisera also react with the native endogenous NBEA when used for immunocytochemistry in cell-lines or in primary cultures of neurons as well as for immunohistochemistry on mouse sections. The sequences of the peptides used for the

5 production of the 3 anti-NBEA antisera are:

anti-NBEA1: KVSDDILGNSDRPGS

anti-NBEA2: IEDLSQSQSPESETDY

anti-NBEA3: YPGCDAGIRAMDLSHD

#### 10 EXAMPLE 4

##### Brain specific expression of NBEA

Expression analysis, by mean of Northern blot revealed an abundant transcript of 11.9 kb in the human brain (Fig.4), which is in agreement with the brain-specific expression pattern of the mouse *Nbea* (Wang *et al.*, J. Neurosci., vol. 20, p. 8551, 2000) and with the expected length of the transcript. *NBEA* is also slightly expressed in the skeletal muscles, the kidney and the

heart. No expression could be detected in the placenta, the lung, the liver or the pancreas.

Expression of neurobeachin in the adult mouse and during mouse development was further investigated by *in situ* hybridization (whole mount and on sections) and immunohistochemistry analyses. For *in situ* hybridization experiments two different riboprobes, choosen along the

20 cDNA sequence of *NBEA*, were used. Rabbit polyclonal antibodies directed against two different epitopes of NBEA were applied in immunohistochemistry experiments.

Both techniques gave an overlapping pattern of expression, assuring specificity.

Whole mount *in situ* hybridizations of developing embryos showed that *NBEA* is expressed at stages as early as E7.5 (also detected by RT-PCR). In these early stages of development (E7.5-25 B9.5) the expression of *NBEA* is rather ubiquitous (Fig. 5a). Later stages (E10.5-E12.5) revealed a more specific pattern of expression in the branchial arches, the nose, the limbs and the tail (Fig. 5b).

However on slides of the late developing embryo (E15-E17) the expression appeared to be rather limited the cells of the CNS and derivative tissues and especially in cells of the cortical

30 plate that have already migrated and are differentiated into neurons (data not shown).

In adult brain neurobeachin is broadly expressed, but very specific in neuronal cells. Particularly high expression was observed in the hippocampus (Fig. 6), in the cerebellum (Fig. 7) and in the cerebral cortex.

## EXAMPLE 5

Identification of MARCKS and PKA as putative interacting partners of neurobeachin by yeast two-hybrid screening

- 5 The Matchmaker Two-hybrid System 2 was purchased from CLONTECH (Palo Alto, CA). All experiments were performed in the yeast reporter strain CG-1945 (Trp<sup>-</sup> and Leu<sup>-</sup>). The "bait" constructs consisted of parts of the human NBEA cloned into the yeast vector pGBKT7 (CLONTECH). Bait pvw4b comprises the PKA binding domain of NBEA, i.e. amino acids 1029 to 1473, bait pvw8b comprises the BEACH domain and the WD-40 repeats, i.e. amino acids 2254 to 2946, bait pvw9 comprises the PH-like and the BEACH domains, i.e. amino acids 2129 to 2614, bait pvw9b comprises the PH-like and the BEACH domains and the WD-40 repeats, i.e. amino acids 2129 to 2946. The pGBKT7 vector allows the fusion of the protein of interest to the C-terminal end of the GAL4 DNA-binding domain and contains *TRP1*<sup>and</sup> Kan<sup>r</sup> reporter genes for selection of transformants. The NBEA bait constructs did not show
- 10 autonomous transcriptional activation and hence were good candidates for the detection of protein interactions in the yeast two-hybrid transcriptional activation assay. An oligo(dT)- and randomly primed "prey" cDNA library from 12.5-day-old embryonic mice cloned into the pACT2 vector was kindly provided by Drs. K. Verschuere and D. Huylebroeck (University of Leuven and Flanders Interuniversity Institute for Biotechnology, Belgium). The pACT2 vector
- 15 allows the fusion of proteins to the C-terminal end of the major GAL4 activation domain and contains *LEU2* and Amp<sup>r</sup> for selection of transformants.  $1 \times 10^9$  CG-1945 yeast were transformed with 66 µg of bait-DNA and 33 µg of prey-library-DNA using a LiAc high efficiency transformation protocol (Gietz, R.D. Yeast 1995; 11: 355-360). This yeast strain contains the *HIS3* and *lacZ* reporter genes under the control of promoters containing GAL4
- 20 binding sites. Transformants were grown for 10 days at 30 °C on triple selective (lacking Trp, Leu, and His) synthetic dropout (SD<sup>-</sup>) agar plates containing 10 mM 3-aminotriazol (Sigma). Double transformed His<sup>+</sup> yeast colonies were restreaked on new SD<sup>-</sup> agar plates and grown for another 24-48 h. For the qualitative measurement of β-galactosidase activity, colony lift filter assays were performed according to standard protocols. Plasmid DNA was isolated from
- 25 positive (blue) colonies by glass bead lysis, extraction with phenol/chloroform, and ethanol precipitation and subsequently used to transform the *Escherichia coli* by electroporation. pACT2 plasmids containing different inserts as analyzed by PCR amplification and *Bgl*III digestion were reassayed by cotransformation into yeast-competent cells with either the bait
- 30

construct used to fish the candidate, or an irrelevant bait construct, or the empty pGBKT7 vector. Plasmids that generated colonies on SD<sup>-</sup> agar plates and were positive in the X-gal filter assay with the NBEA bait constructs were considered for further analysis. In this way, the mouse myristoylated alanine-rich C kinase substrate (Marcks, fished with bait pvw8b and pvw9b) and protein kinase A (PKA, fished with bait pvw6c) were identified as most probable interacting partners of NBEA. The interaction with PKA is in agreement with the surface plasmon resonance measurements experiments of co-immunoprecipitations of Wang *et al.* (J. Neurosci., vol. 20, p. 8551, 2000).

## 10 EXAMPLE 6

### Yeast expression of neurobeachin

Yeast deletion strains: Genomic deletions of specific genes can be made in the *S. cerevisiae* W303-1A strain (Thomas, B.J. and Rothstein, R.J., Cell 1989; 56: 619-630), the BY4741 strain (Brachmann *et al.*, Yeast 1998; 14: 115-132) or the  $\Delta$ 1278b strain (Kron, S.J. Trends Microbiol. 1997;5:450-454) as indicated. They can be obtained by PCR product-directed gene disruption as described previously (Brachmann *et al.*, Yeast 1998; 14: 115-132) using oligonucleotides described in WO02068663A1 Van Leuven and Windemincx, and using the pRS vectors as templates for auxotrophic selectable markers. Deletions were checked by Southern Blot analysis (Sambrook *et al.* Molecular Cloning, a Laboratory Manual, 2nd edn. 1989; Cold Spring Harbor, N.Y.: Cold Spring Harbor Laboratory Press) or by PCR analysis. The PKA deletion strains ASY62 and ASY63 were kindly provided by S. Garrett and have been described previously (Smith A. *et al.*, EMBO J., 1998; 17:3556-3564). The NBEA cDNA can be transformed in yeast as recombinant constructs that contained the triose phosphate isomerase (TPI) promoter (Alber T, Kawasaki G., J Mol Appl Genet 1982;1:419-434); allowing the NBEA-cDNAs to be constitutively expressed. For this purpose, the neurobeachin cDNA, can be ligated into the *Eco*RI-*Xho*I sites of the yeast/*E.coli* shuttle vector pJW212 which is a derivative of pYX212 (R&D systems Europe Ltd., Abingdon, UK). The cloning of the cDNA inserts can be confirmed by sequence analysis using a method based on the standard dideoxy sequence analysis (Sanger *et al.*, Proc. Natl. Acad. Sci. USA 1977;74: 5463-5467). The resulting neurobeachin-expression plasmids can be transformed into the appropriate yeast strains according to the protocol outlined by Gietz R.D. and Schiestl R.H. (Methods in Molecular and Cellular Biology 1995;5: 255-269). Transformed cells can be

plated on selective glucose-containing medium without uracil (SD-ura) as specified by Sherman *et al.* (Methods in Yeast Genetics. 1986; Cold Spring Harbor, N.Y.: Cold Spring Harbor Laboratory Press).

- 5 Yeast culture: Yeast cells can be cultured in YEP medium (2% (w/v) bacto peptone, 2% (w/v) yeast extract) or in the appropriate selective medium in order to maintain plasmids in transformed strains. Media can be supplemented with 4% (w/v) glucose (YPD or SD). For pseudohyphal growth, cells can be plated on nitrogen limitation medium (1mM asparagine; 0.17% (w/v) yeast nitrogen base without amino acids and without  $\text{NH}_4\text{SO}_4$ , 2% (w/v) glucose and 1.5% (w/v) agar). Cells are mostly grown at 30°C or 25°C for different time periods as specified.

- 15 Preparation of crude extracts for Western blotting: Yeast cells can be inoculated at a density of  $\text{OD}_{600}$  of 0.2 in 5 ml selective medium and grown for 16 hours at 30°C. One milliliter of the culture can then be transferred to a microcentrifuge tube and chilled on ice. After fast harvesting of the cells by centrifugation in a cooled (4°C) microcentrifuge at maximal speed for 15 s and the pellet can be resuspended in 50µl prewarmed (95°C) standard SDS-PAGE sample buffer. After boiling the mixture for 15 min in order to denature and inactivate all enzymes it then can be processed by Western blot analysis as described below.

- 20 Western Blotting: The denatured and reduced protein mixtures can be separated by SDS-PAGE as performed under reducing conditions on either 4-20% linear gradient gels or on 8% or 12% homogenous gels (Novex, San Diego, CA). After electrophoresis, the proteins are normally electrophoretically transferred to nitro-cellulose filters (Hybond-C, Amersham, UK) or to PVDF filters (ABI, San Fransisco, CA). The filters can be blocked by incubation for 1 hour in PBS with 0.05% (v/v) Tween 20 and 5% (w/v) skimmed dried milk (blocking buffer). The filters can then be incubated overnight with a specified monoclonal antibody or a specified polyclonal antiserum appropriately diluted in same blocking buffer. After washing the filters three times in Tween-PBS and they can be treated for 1.5 h at room temperature with horseradish peroxidase-labelled rabbit anti-mouse IgG (Dakopatts, Denmark) diluted 1/3000 in blocking buffer. After three washes in Tween-PBS, streptavidine-biotinylated horseradish peroxidase complex (Amersham), diluted 1/250 in blocking buffer, can be applied for 1.5 h at room temperature. Thereafter, the filters are usually washed three times in Tween-



PBS and once in PBS. And the filters are then to be incubated in PBS containing 0.05% (w/v) diaminobenzidine and 0.03% (v/v) hydrogen peroxide until background staining develops.

It should be clear that the formation of an immunological complex between the monoclonal antibodies and the antigen is not limited to the precise conditions described above, but that all

- 5 techniques that respect the immunochemical properties of the antibody and antigen binding will produce similar formation of an immunological complex.

The detection of the immunologically bound monoclonal antibody can be achieved by conventional technology known and comprised in the art, with a second antibody that itself carries a marker or a chemical or physical group as a marker.

10

Microscopy: Yeast cells grown on pseudohyphae-inducing nitrogen limitation medium can be scraped from plate, mixed with water and mounted on glass slides. Images can be processed with a laser microscope (e.g. ZEISS-axioplan) under a 100x oil-immersion objective.

## 15 **EXAMPLE 7**

**Lentiviral transfer and locoregional expression of neurobeachin in the brain**

### Animals

- 20 Female C57BL/6 mice and Wistar rats of 8 weeks old are usually used. The animals usually are housed under 14 h light/10 h dark cycle with free access to food and water.

### Lentiviral vector production

- 25 HIV-1-derived vector particles, pseudotyped with the envelope of vesicular stomatitis virus (VSV), can be produced by transfecting 293T cells (commonly available human embryonic kidney cell line) with a packaging plasmid encoding viral gag and pol proteins (pCMVAR8.91), a plasmid encoding the envelope of vesicular stomatitis virus (pMDG) and a plasmid encoding a human wild type neurobeachin flanked by long terminal repeat sequences LTRs (pHMWS-MBEAh). All plasmids are described in Naldini L., *et al.* (1996) Science 272: 263-267 and Zufferey R., *et al.* (1997) Nature Biotechnology 15:871-875.

- 30 The construction of vector plasmid pHR' has been described by Verma *et al.*, US 6,013,516. The basic construct pHMWS from the original pHR' construct by including a multiple cloning site (MCS or M) behind the internal CMV promoter, the woodchuck hepatitis regulatory element (WPRE or W) and deletion of part of the LTR has been described by Veerle

Backelandt *et al.* Hum-Gene-Ther. 2002 May 1; 13(7): 841-53. The development of self-inactivating vectors (S), in which the viral promoter in the LTR is inactivated during reverse transcription, precludes oncogene activation and vector rescue. (Zufferey R, *et al.* (1998) Journal of Virology 72:9873-9880). Finally, the posttranscriptional cis-acting regulatory element of the woodchuck hepatitis virus (W) has been inserted to increase transgene expression (Zufferey R, *et al.* (1999). J Virol 73:2886-2892). The gene encoding neurobeachin was cloned in the MCS of the pHMWS plasmid using *SpeI* and *KpnI*. Neurobeachin was also cloned in the pHMIRENeo transfer plasmid to create stable cell lines of SKNSH overexpressing neurobeachin. This transfer plasmid can be constructed from the pHMS construct by including IRES and Neo elements. Veerle Backelandt *et al.* Hum-Gene-Ther. 2002 May 1; 13(7): 841-53.

Transient transfection of 293-T cells was carried out in 10 cm dishes. Per plate a mixture (700  $\mu$ l) containing 20  $\mu$ g of vector plasmid, 10  $\mu$ g of packaging construct and 5  $\mu$ g of envelope plasmid was made in 150 mM NaCl. To this DNA solution 700  $\mu$ l of a PEI solution (110  $\mu$ l of a 10 mM stock solution in 150 mM NaCl) was added slowly. After 15 min at room temperature, the DNA-PEI complex was added dropwise to the 293T cells in DMEM medium with 1% FCS. After overnight incubation, medium was replaced with medium containing 10% FCS. Supernatants were collected from day two to five post-transfection, clarified by low speed centrifugation and filtered through a 0.45  $\mu$ m filter. The vector particles were sedimented by ultracentrifugation in a swinging-bucket rotor (SW27 Beckman, Palo alto, CA) at 25, 000 rpm for 2 hr at 4°C. Pellets were redissolved in PBS resulting in a 100-fold concentration. For injections into the brain, an additional centrifugation is performed in a fixed angle rotor (Biofuge Stratos, Heraeus Instruments, Hanau Germany) at 20, 000 rpm at 4°C for 1 hr.

### Surgery

All surgical procedures were performed under chloral hydrate anaesthesia (400 mg/kg i.p.) using aseptic procedures. The mice were placed in a stereotactic head frame (Narishige), and after midline incision of the skin, 1 or 2 small holes were drilled in the skull in the appropriate location using Bregma as reference. The coordinates used were: striatum mouse (AP 0.5, LAT 2.0, DV 3.0-2.0), substantia nigra rat (target AP -5.2, L 2.3, DV 7.3). Two  $\mu$ l of highly concentrated vector (108 pg p24/ml) supplemented with 4  $\mu$ g/ml polybrene was injected at a

rate of 0.25  $\mu$ l/min with a 30G needle connected by a microdialysis tubing to a 10  $\mu$ l Hamilton syringe in a microinjection pump (CMA). In some animals, 2  $\mu$ l of 0.9% NaCl solution was injected in the contralateral hemisphere as control. After the injection, the needle was left in place for an additional 10 minutes before being slowly withdrawn from the brain (adapted from Dull T, *et al.* (1998) J Virol 72:9873-9880).

### Histology

To assess lentiviral transduction, the mice were deeply anaesthetised with pentobarbital and perfused transcardially with saline followed by ice-cold 4% paraformaldehyde in PBS for 15 minutes. The brain was removed from the skull and postfixed overnight in the same fixing solution. 50  $\mu$ m thick coronal brain sections were cut with a vibratome and stored at 4°C in PBS buffer containing 0.1% sodium azide. The sections were treated with 3% hydrogen peroxide and preincubated in 5% normal swine serum with 0.1% Triton X-100 in PBS. Incubation with the primary antibody in 5% normal swine serum and 0.1% Triton X-100 was overnight at room temperature. The sections were then incubated in biotinylated swine anti-rabbit secondary antibody, followed by an incubation with Strept-ABC-HRP complex (Dako, Glostrup, Denmark). Detection was with diaminobenzidine (DAB) using H<sub>2</sub>O<sub>2</sub> as a substrate. For immunofluorescence, sections were incubated overnight with one or two primary antibodies. Detection was with a secondary biotinylated antibody followed by Texas Red-conjugated streptavidin (Jackson ImmunoRes Lab., West Grove, Pennsylvania) and/or a FITC-conjugated secondary antibody (donkey anti-mouse, Jackson ImmunoRes Lab.; swine anti-rabbit, DAKO). Primary antibodies used were a rabbit polyclonal anti-neurobeachin or a mouse monoclonal antineurobeachin. Analysis was done on a NIKON inverted microscope DIAPHOT 300 connected to a Bio-Rad MRC1024 confocal microscope and images were captured by Laserssharp (version 3.2) and processed using Adobe Photoshop 5.5 (Adobe, CA). Fluoro-Jade B histochemistry was used to detect degenerating neurons according to the manufacturer's protocol (Histo-Chem, Jefferson, Arkansas).

### Cell culture and lentiviral vector transduction

Primary culture of hippocampal or cerebellar neurons or AtT-20 (mouse tumor cells of the pituitary, ATCC CRL-1795) or Neuro-2A (mouse neuroblastoma cells, ATCC CCL-131) or SK-N-SH cells (human neuroblastoma cells, ATCC HTB11) were maintained in Dulbecco's modified Eagle's medium (DMEM) with glutamax (Invitrogen, Belgium) containing 10%

foetal calf serum (FCS), 0.12 % (v/w) sodium carbonate (Invitrogen) and 20 µg/ml gentamycin (Invitrogen) in a 5% humidified CO<sub>2</sub> atmosphere. The day before transduction, we seeded the cells in a 6-well plate. On the day of transduction, medium was replaced by DMEM containing 1% FCS, 4µg/ml polybrene and 4 x 10<sup>6</sup> pg p24 of LV. 5 hours after transduction, we replaced the medium and 2 days post-transduction we harvested the cells with PBS containing 5 mM EDTA. The cells were lysed with SDS containing 10 mM PMSF (Sigma, Belgium) and boiled for 5 minutes. For the production of the stable cell lines we seeded SKNSH cells in a 24-well plate at a density of 100, 000 cells per well. Two days after transduction with 1x10<sup>6</sup> pg p24 of pHMMBEA(WT)IRESNeo or pHMMBEAIRENeo vector, the medium was replaced with medium containing 800 µg/ml geneticine (G418, GICO-BRL). Analysis of expression was performed after 2 weeks of selection.

#### Western Blot analysis

10 µg total protein was diluted in SDS-PAGE loading buffer (25 mM tris-HCl, pH 6.6, 50 mM DTT, 1% SDS, 0.05% bromophenol blue and 5% glycerol) and samples were loaded on a 4-20% SDS-polyacrylamide gel. The proteins were transferred to a PVDF membrane (Bio-Rad, Watford, UK) and detection was performed with a polyclonal rabbit anti-neurobeachin antibody using the ECL+ chemiluminescent system (Amersham-Pharmacia, The Netherlands).

#### Cell counting

We determined the number of neurobeachin positive cells in the striatum by counting every fifth 50µm section at a magnification of 40x. We considered the cells to be positive for neurobeachin if the object to be counted had darker chromagen staining than the surrounding background and could be clearly identified as a cell. We estimated the total number of positive cells per brain by multiplication of the counts by 5 (Abeliovich A, *et al* (2000) Neuron 25:239-252).

#### Lentiviral vectors mediate expression of neurobeachin in cell culture

The expression of neurobeachin from the lentiviral vector constructs, was confirmed by transfecting 293-T and transducing SK-N-SH neuroblastoma cells and western blot analysis. After transduction with vectors containing the antisense neurobeachin we observed a decrease in neurobeachin expression. Two stable SK-N-SH cell lines neurobeachin were selected after transduction with an neurobeachin-IRES-neo vector, analysis of lysates of this stable cell lines

by western blot and immunocytochemistry could reveal expression of high levels of neurobeachin.

Lentiviral vectors mediate expressing of neurobeachin in brains

- 5 Two weeks after injection of vectors encoding neurobeachin in the mouse striatum neurites in the cortex displayed neurobeachin immunoreactivity.

**AUTISM GENE****5 ABSTRACT**

The present invention concerns genes containing mutations associated with autism its onset and development and also to the encoded proteins of said genes associated with autism, its onset and development and the use of said genes, proteins or protein isoforms. The invention thus  
10 also relates to methods of screening for, diagnosis and treatment of autism in human subjects e.g., clinical screening, diagnosis, prognosis, therapy and prophylaxis, as well as for drug screening and drug development.






Figure 1. FISH analysis of metaphase chromosomes of VC cells of the autistic patient using cosmid clone 25I17. Hybridization signals are marked by arrows with a chromosome identity is label.




**Figure 2 . Map of the breakpoint (BP) region in the autistic patient. (A) FISH analysis.** At the BAC level, clone 307O13 is proximal and 66B8 distal to the BP. At the level of cosmids (obtained by cosmid library screening with 66B8\_probe2, 6 and 8, cosmids 32G24 and 7H10 are proximal, and 4B16 is distal to the BP. Cosmids 25I17 and 27F13 span the BP. (B) Restriction map used for Southern blot analysis (Fig. 4) with 66B8\_South probe; the BP is narrowed down to a 2.8 kb *HindIII/BamHI* restriction fragment.






**Figure 3 . Southern blot analysis of genomic DNA from the autistic patient (P) and a control individual (C). Genomic DNA was digested with the mentioned restriction enzymes. Using probe 66B8\_South, rearranged fragments are observed for the *EcoRI* (5.9 kb), *HindIII* (8.7 kb) and *PstI* (11.5 kb) digestions in the patient, in addition to the 8.0 kb, 6.4 kb and 14.7 kb wild type fragments, respectively. In the control, only the wild type fragment is visible.**



**Figure 4. Expression pattern of the hNbea transcript.** Northern blots of total RNA from human tissues (Clontech). The probe used for hybridization is hNbea-ex56. Tissue abbreviations are as followed: B, brain; H, heart; K, kidney; L, liver; Lu, lung; P, pancreas; Pl, placenta; S, skeletal muscle.

A.



B.



Figure 5. Expression of Neurobeachin in mouse embryos. Whole mount *in situ* hybridizations of developing embryos. (A) Ubiquitous expression at stage E7.5. (B) Expression in the limbs, the tail, the branchial arches, and the nose at stage E10.5.

28-10-2003

PCT Application

**BE0300172**

